Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Sony Group Corp (SONY) vs Twist Bioscience Corp (TWST) Price & Performance

Sony Group CorpTrade
Twist Bioscience CorpTrade

Price performance (Past 24H)

Key statistics

Sony Group Corp vs Twist Bioscience Corp — how do they compare? Sony Group Corp trades at $23.58 (market cap $139.99B), while Twist Bioscience Corp trades at $124 (market cap $7.82B). The key difference: Sony Group Corp is far larger — about 17.9× Twist Bioscience Corp's market cap, and Sony Group Corp pays a 0.67% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.

SONYTWST
Market Cap
$139.99B$7.82B
Sector
TechnologyHealth
52-Week High
$30.26$124.88
52-Week Low
$19.32$24.16
Enterprise Value
$137.89B$7.75B
Dividend Yield
0.67%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Sony Group Corp

Sony stock trades at $23.46, up 1.56% with bullish technical indicators and strong analyst support. The company shows solid revenue growth with $12.96T in 2025 sales and improved profitability, though 2026 projections indicate potential margin pressure. Recent catalysts include the record-breaking Spider-Man film performance and a $6.3B joint venture with TSMC for next-generation image sensors, positioning Sony for continued entertainment and technology leadership.

Sony presents a compelling investment case with strong entertainment franchises and technological innovation, though investors should monitor execution risks in the gaming transition and potential margin compression. Wall Street remains overwhelmingly bullish with 11 buy ratings and a 29.75% upside potential, but the stock faces challenges from currency volatility and competitive pressures in key markets.

Twist Bioscience Corp

Twist Bioscience (TWST) trades at $115.67, up 6.04% in the last session, with bullish technical signals from moving averages and a recent analyst upgrade. Revenue growth is strong, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, though the company remains unprofitable with negative net income margins. A recent $300 million public offering at $96 per share indicates capital raising for expansion.

The outlook is mixed: robust revenue growth and high analyst buy ratings (78.57%) support upside potential, but persistent losses, cash burn, and high valuation ratios pose significant risks. Investors should weigh growth prospects against financial sustainability concerns.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Sony Group Corp

Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.

Read more on SONY

About Twist Bioscience Corp

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.

Read more on TWST